Ratings by Guggenheim (Eddie Hickman)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 6/10/2026 | Zevra Therapeutics, Inc. | ZVRA | Maintain | Buy (N/A) |
|
Details | ||
| 5/8/2026 | Zevra Therapeutics, Inc. | ZVRA | Maintain | Buy (N/A) |
|
Details | ||
| 3/10/2026 | GH Research PLC | GHRS | Maintain | Buy (N/A) |
|
Details | ||
| 3/10/2026 | Zevra Therapeutics, Inc. | ZVRA | Maintain | Buy (N/A) |
|
Details | ||
| 2/6/2026 | ProMIS Neurosciences | PMN | Maintain | Buy (N/A) |
|
Details | ||
| 1/5/2026 | GH Research PLC | GHRS | Maintain | Buy (N/A) |
|
Details | ||
| 12/3/2025 | Cybin Inc. | CYBN | Maintain | Buy (N/A) |
|
Details | ||
| 11/18/2025 | ProMIS Neurosciences | PMN | Maintain | Buy (N/A) |
|
Details | ||
| 11/5/2025 | Tarsus Pharmaceuticals | TARS | Maintain | Buy (N/A) |
|
Details | ||
| 8/28/2025 | Outlook Therapeutics Incs. | OTLK | Downgrade | Neutral (Buy) |
2.38 (1.68) |
-29.41% | Details | |
| 5/9/2025 | GH Research PLC | GHRS | Maintain | Buy (N/A) |
|
Details | ||
| 5/2/2025 | Tarsus Pharmaceuticals | TARS | Maintain | Buy (N/A) |
|
Details | ||
| 4/9/2025 | Outlook Therapeutics Incs. | OTLK | Maintain | Buy (Buy) |
|
Details | ||
| 3/13/2025 | Zevra Therapeutics, Inc. | ZVRA | Maintain | Buy (N/A) |
|
Details | ||
| 3/13/2025 | GH Research PLC | GHRS | New Coverage | Buy (N/A) |
10.82 (24.60) |
127.36% | Details | |
| 3/13/2025 | Cybin Inc. | CYBN | New Coverage | Buy (N/A) |
7.15 (8.28) |
15.8% | Details | |
| 2/26/2025 | Tarsus Pharmaceuticals | TARS | Maintain | Buy (N/A) |
|
Details | ||
| 2/3/2025 | Zevra Therapeutics, Inc. | ZVRA | Maintain | Buy (N/A) |
|
Details | ||
| 12/16/2024 | ProMIS Neurosciences | PMN | New Coverage | Buy (N/A) |
0.93 (10.24) |
1001.08% | Details | |
| 11/29/2024 | Tarsus Pharmaceuticals | TARS | Maintain | Buy (Buy) |
|
Details | ||
| 10/11/2024 | Tarsus Pharmaceuticals | TARS | Maintain | Buy (Buy) |
|
Details | ||
| 10/4/2024 | Tarsus Pharmaceuticals | TARS | Maintain | Buy (Buy) |
|
Details | ||
| 1/25/2024 | Outlook Therapeutics Incs. | OTLK | Upgrade | Buy (Neutral) |
0.40 (2.38) |
495% | Details | |
| 8/30/2023 | Outlook Therapeutics Incs. | OTLK | Downgrade | Neutral (Buy) |
1.41 (1.68) |
19.15% | Details | |
| 5/18/2023 | Tarsus Pharmaceuticals | TARS | New Coverage | Buy (N/A) |
15.93 (67.11) |
321.28% | Details | |
| 5/1/2023 | Iveric Bio | ISEE | Downgrade | Neutral (Buy) |
32.89 (39.95) |
21.47% | Details | |
| 11/18/2022 | Impel Neuropharma | IMPL | Maintain | Buy (N/A) |
|
Details | ||
| 9/6/2022 | Iveric Bio | ISEE | Maintain | Buy (N/A) |
|
Details | ||
| 9/7/2021 | Impel Neuropharma | IMPL | Maintain | Buy (N/A) |
|
Details |
